Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review (Q38052918)

27 August 2017

0 references

Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review (English)

1 reference

27 August 2017

1 reference

metastatic colon cancer

1 reference

1 reference

1 reference

Cheng-Bo Han

1

1 reference

27 August 2017

Fan Li

series ordinal

2

1 reference

27 August 2017

Jie-Tao Ma

series ordinal

3

1 reference

27 August 2017

Hua-Wei Zou

series ordinal

4

1 reference

27 August 2017

publication date

17 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

30

1 reference

27 August 2017

issue

10

1 reference

27 August 2017

page(s)

741-747

1 reference

Expression of epidermal growth factor-receptor related protein (ERRP) in human colorectal carcinogenesis.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

PTEN status in advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Stability of K-ras mutations throughout the natural history of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Allelotyping analyses of synchronous primary and metastasis CIN colon cancers identified different subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Molecular changes in the Ki-ras and APC genes in primary colorectal carcinoma and synchronous metastases compared with the findings in accompanying adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

High sensitivity of both sequencing and real-time PCR analysis of KRAS mutations in colorectal cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

KRASMutations and Anti–Epidermal Growth Factor Receptor Therapy in Colorectal Cancer With Lymph Node Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357907.2012.732159

10.3109/07357907.2012.732159

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference